Tyler Zeronda Vyne Therapeutics Inc. (VYNE) insider trading activity

Tyler Zeronda is CHIEF FINANCIAL OFFICER of VYNE Therapeutics Inc.. Currently has a direct ownership of 131,567 shares of VYNE, which is worth approximately $417,067. The most recent transaction as insider was on Sep 30, 2024, when has been sold 84 shares (Common Stock) at a price of $1.88 per share, resulting in proceeds of $157. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 132K

0.06% 3M change

89.5% 12M change

Total Value Held $417,067

Tyler Zeronda Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	SELL Payment of exercise price or tax liability	$157 $1.88 p/Share	84 Reduced 0.06%	131,567 Common Stock
Jul 01 2024	SELL Payment of exercise price or tax liability	$176 $1.92 p/Share	92 Reduced 0.07%	131,651 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$289 $3.08 p/Share	94 Reduced 0.07%	131,743 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$212 $2.28 p/Share	93 Reduced 0.07%	131,837 Common Stock
Jan 01 2024	BUY Grant, award, or other acquisition	-	62,500 Added 32.15%	131,930 Common Stock
Dec 13 2023	BUY Grant, award, or other acquisition	-	62,500 Added 47.37%	69,430 Common Stock
Oct 02 2023	SELL Payment of exercise price or tax liability	$4,163 $3.83 p/Share	1,087 Reduced 13.56%	6,930 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$373 $4.1 p/Share	91 Reduced 1.12%	8,017 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$1,182 $3.08 p/Share	384 Reduced 4.52%	8,108 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$53 $0.15 p/Share	354 Reduced 0.2%	173,005 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$78 $0.22 p/Share	353 Reduced 0.2%	173,359 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$138 $0.39 p/Share	354 Reduced 0.2%	173,712 Common Stock
May 31 2022	BUY Grant, award, or other acquisition	$4,378 $0.35 p/Share	12,510 Added 6.71%	174,066 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$502 $0.65 p/Share	773 Reduced 0.48%	161,556 Common Stock
Mar 17 2022	BUY Grant, award, or other acquisition	-	75,000 Added 31.6%	162,329 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$210 $1.02 p/Share	206 Reduced 0.24%	87,329 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$3,685 $0.88 p/Share	4,187 Added 4.56%	87,535 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$286 $1.39 p/Share	206 Reduced 0.25%	83,348 Common Stock
Sep 02 2021	BUY Grant, award, or other acquisition	-	60,859 Added 42.14%	83,554 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$2,457 $3.51 p/Share	700 Reduced 2.99%	22,695 Common Stock

Tyler Zeronda

CHIEF FINANCIAL OFFICER

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VYNE shares.

Notify only if

Value

Insider Trading

Get notified when an Vyne Therapeutics Inc. insider buys or sells VYNE shares.

Notify only if

Operation

Value

Type

News

Receive news related to VYNE Therapeutics Inc.

Track Activities on VYNE

Account